Skip to main content
Clinical Trials/NCT03199703
NCT03199703
Completed
Not Applicable

Randomized Trial of Conventional Versus Radiofrequency Needle Transseptal Puncture for Cryoballoon Ablation

Jason Andrade6 sites in 1 country135 target enrollmentJanuary 17, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Jason Andrade
Enrollment
135
Locations
6
Primary Endpoint
Total time required for left atrial access
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This will be a prospective single-blinded, randomized, controlled trial comparing the effectiveness and safety of transseptal puncture using the Baylis transseptal system to transseptal left atrial access with standard transseptal equipment (usual care) in patients undergoing catheter ablation procedures for atrial fibrillation with the cryoballoon system.

The targeted population will consist of patients with symptomatic paroxysmal atrial fibrillation undergoing pulmonary vein isolation with the cryoballoon system.

Detailed Description

Study Objective - The objective of the prospective, randomized study is to evaluate the effectiveness and safety of the Baylis transseptal system (RF needle, TorFlex sheath, and specialised ProTrack guidewire) compared with a conventional transseptal (conventional sheath, Brockenbrough needle, and standard guidewire) for transseptal LA access during cryoballoon ablation procedures. Trial design - This will be a prospective single-blinded, randomized, controlled trial comparing the effectiveness and safety of transseptal puncture using the Baylis transseptal system to transseptal left atrial access with standard transseptal equipment (usual care) in patients undergoing catheter ablation procedures for atrial fibrillation with the cryoballoon system. Study Population - The targeted population will consist of patients with symptomatic paroxysmal atrial fibrillation undergoing pulmonary vein isolation with the cryoballoon system.

Registry
clinicaltrials.gov
Start Date
January 17, 2017
End Date
August 1, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Jason Andrade
Responsible Party
Sponsor Investigator
Principal Investigator

Jason Andrade

MD FRCPC FHRS

University of British Columbia

Eligibility Criteria

Inclusion Criteria

  • Non-permanent AF documented on a 12 lead ECG, Trans Telephonic Monitoring (TTM) or Holter monitor within the last 24 months
  • Age of 18 years or older on the date of consent
  • Candidate for ablation based on AF that is symptomatic
  • Informed Consent

Exclusion Criteria

  • Previous left atrial (LA) ablation or LA surgery
  • AF due to reversible cause (e.g. hyperthyroidism, cardiothoracic surgery)
  • Active Intracardiac Thrombus
  • Pre-existing pulmonary vein stenosis or PV stent
  • Pre-existing hemidiaphragmatic paralysis
  • Contraindication to anticoagulation or radiocontrast materials
  • Left atrial anteroposterior diameter greater than 5.5 cm by transthoracic echocardiography
  • Cardiac valve prosthesis
  • Clinically significant (moderately-severe, or severe) mitral valve regurgitation or stenosis
  • Myocardial infarction, PCI / PTCA, or coronary artery stenting during the 3-month period preceding the consent date

Outcomes

Primary Outcomes

Total time required for left atrial access

Time Frame: Intraprocedural assessment (within 24 hours)

defined as time from the first pull-down of the needle/sheath/dilator apparatus in the superior vena cava to first entrance of the cryoballoon into the left atrium.

Secondary Outcomes

  • Plastic Shavings(Intraprocedural assessment of visible plastic shavings (within 24 hours))
  • Transseptal time - left atrial access to sheath positioning(Intraprocedural assessment (measured in seconds))
  • Transeptal Access(Intraprocedural assessment (within 24 hours))
  • The proportion of patients sustaining a procedural complication plausibly related to transseptal puncture(Acute peri-procedural complications will be defined as occurring within 30 days of ablation)
  • Transseptal time - septal engagement to sheath advancement(Intraprocedural assessment (measured in seconds))

Study Sites (6)

Loading locations...

Similar Trials